NVCR · Insider Trading
NovoCure Limited Ordinary Shares
Every open-market purchase and sale reported by NVCR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Michal Nath Puri | Chief Human Resources Officer | A | +1,905 | +$21.24K |
| 2026-07-01 | Arye Barak Ben | General Counsel | A | +1,299 | +$14.48K |
| 2026-07-01 | Frank X Leonard | Chief Executive Officer | A | +1,905 | +$21.24K |
| 2026-07-01 | Asaf Danziger | Director | A | +268 | +$2.99K |
| 2026-06-05 | Frank X Leonard | Chief Executive Officer | Sell | −34,273 | −$614.63K |
| 2026-06-05 | Kristin Stafford | Director | A | +11,610 | — |
| 2026-06-05 | Gabriel Leung | Director | A | +11,610 | — |
| 2026-06-05 | Timothy J Scannell | Director | A | +11,610 | — |
| 2026-06-05 | W Anthony Vernon | Director | A | +11,610 | — |
| 2026-06-05 | Jeryl L Hilleman | Director | A | +11,610 | — |
| 2026-06-05 | Allyson J Ocean | Director | A | +11,610 | — |
| 2026-06-05 | Martin J. Madden | Director | A | +11,610 | — |
| 2026-06-05 | David Hung | Director | A | +11,610 | — |
| 2026-06-03 | Timothy J Scannell | Director | Sell | −2,945 | −$46.44K |
| 2026-06-03 | David Hung | Director | Sell | −2,945 | −$46.44K |
| 2026-06-03 | Gabriel Leung | Director | Sell | −2,945 | −$46.44K |
| 2026-06-03 | Jeryl L Hilleman | Director | Sell | −2,945 | −$46.44K |
| 2026-06-03 | Kristin Stafford | Director | Sell | −2,945 | −$46.44K |
| 2026-06-03 | Allyson J Ocean | Director | Sell | −2,945 | −$46.44K |
| 2026-06-03 | W Anthony Vernon | Director | Sell | −2,945 | −$46.44K |
| 2026-04-28 | W Anthony Vernon | Director | M | +21,500 | +$244.88K |
| 2026-03-05 | Ashley Cordova | Former Chief Executive Officer | F | −17,638 | −$234.59K |
| 2026-03-05 | Arye Barak Ben | General Counsel | A | +50,125 | — |
| 2026-03-05 | Christoph Brackmann | Chief Financial Officer | MIXED | +48,725 | −$85.31K |
| 2026-03-05 | Uri Weinberg | Chf Medical and Innovation Ofr | MIXED | +43,713 | −$85.31K |
| 2026-03-05 | Nicolas Leupin | Former Chief Medical Officer | Sell | −1,100 | −$14.64K |
| 2026-03-05 | Mukund Paravasthu | Chief Operating Officer | MIXED | −3,511 | −$667.21K |
| 2026-03-05 | Michal Nath Puri | Chief Human Resources Officer | MIXED | +39,000 | −$14.64K |
| 2026-03-05 | William F Doyle | Executive Chairman | MIXED | +328,397 | −$932.88K |
| 2026-03-05 | Frank X Leonard | Chief Executive Officer | MIXED | +144,393 | −$74.60K |
| 2026-03-03 | Nicolas Leupin | Former Chief Medical Officer | Sell | −1,029 | −$14.06K |
| 2026-03-03 | Mukund Paravasthu | Chief Operating Officer | Sell | −1,963 | −$26.75K |
| 2026-03-03 | Arye Barak Ben | General Counsel | A | +17,755 | — |
| 2026-03-03 | Frank X Leonard | Chief Executive Officer | MIXED | +1,655 | −$230.58K |
| 2026-03-03 | Michal Nath Puri | Chief Human Resources Officer | Sell | −1,441 | −$19.69K |
| 2026-03-03 | Uri Weinberg | Chf Medical and Innovation Ofr | MIXED | +2,259 | −$146.86K |
| 2026-03-03 | Ashley Cordova | Former Chief Executive Officer | MIXED | +2,639 | −$290.44K |
| 2026-01-12 | Mukund Paravasthu | Chief Operating Officer | F | −2,133 | −$30.61K |
| 2025-11-04 | Michal Nath Puri | Chief Human Resources Officer | F | −752 | −$9.64K |
| 2025-11-04 | Frank X Leonard | EVP, Pres., Novocure Oncology | F | −966 | −$12.37K |
| 2025-11-04 | Christoph Brackmann | Chief Financial Officer | F | −7,033 | −$86.01K |
| 2025-11-04 | Mukund Paravasthu | Chief Operating Officer | F | −3,117 | −$38.22K |
| 2025-09-08 | Ashley Cordova | Chief Executive Officer | Buy | +81,550 | +$996.86K |
| 2025-07-30 | Christoph Brackmann | Chief Financial Officer | Buy | +20,000 | +$231.80K |
| 2025-07-01 | Asaf Danziger | Director | A | +833 | +$12.60K |
| 2025-07-01 | Michal Nath Puri | Chief Human Resources Officer | A | +833 | +$12.60K |
| 2025-07-01 | Frank X Leonard | EVP, Pres., Novocure Oncology | A | +833 | +$12.60K |
| 2025-07-01 | Ashley Cordova | Chief Executive Officer | A | +833 | +$12.60K |
| 2025-07-01 | Arye Barak Ben | General Counsel | A | +769 | +$11.63K |
| 2025-06-06 | Frank X Leonard | EVP, Pres., Novocure Oncology | A | +179,426 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| William F Doyle | Executive Chairman | 766,564 | $11.83M |
| Frank X Leonard | Chief Executive Officer | 461,425 | $7.12M |
| Ashley Cordova | Former Chief Executive Officer | 422,570 | $6.52M |
| Asaf Danziger | Chief Executive Officer | 416,742 | $6.43M |
| Uri Weinberg | Chf Medical and Innovation Ofr | 267,190 | $4.12M |
| Arye Barak Ben | General Counsel | 243,752 | $3.76M |
| W Anthony Vernon | Director | 209,267 | $3.23M |
| Michal Nath Puri | Chief Human Resources Officer | 203,227 | $3.14M |
| Christoph Brackmann | Chief Financial Officer | 182,842 | $2.82M |
| Mukund Paravasthu | Chief Operating Officer | 121,455 | $1.87M |
| Nicolas Leupin | Former Chief Medical Officer | 102,979 | $1.59M |
| Gabriel Leung | Director | 101,109 | $1.56M |
| David Hung | Director | 32,075 | $494.92K |
| Martin J. Madden | Director | 30,668 | $473.21K |
| Timothy J Scannell | Director | 25,898 | $399.61K |
| Jeryl L Hilleman | Director | 25,471 | $393.02K |
| Allyson J Ocean | Director | 22,934 | $353.87K |
| Kristin Stafford | Director | 22,934 | $353.87K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NVCR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.